Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Glaxo and Genmab Drop IV Version of Immune Drug

By Pharmaceutical Processing | September 16, 2010

NEW YORK (AP) — GlaxoSmithKline PLC and Genmab A/S will end the development of an intravenous form of a drug intended to treat autoimmune diseases like lupus and multiple sclerosis, and focus on an injectable version.

The companies said an injectable version of Arzerra should be more convenient for patients and have fewer side effects. The drug can also be used to treat rheumatoid arthritis.

Based on from a recent study of Arzerra in multiple sclerosis, GlaxoSmithKline will start a new trial of the drug in 2011. The results from that study were announced Friday. GlaxoSmithKline is solely responsible for developing the drug as a treatment for autoimmune disorders. The companies are codeveloping the drug as a treatment for cancer.

Arzerra is approved as a treatment for chronic lymphocytic leukemia in patients who have received at least one previous therapy. The companies are also testing it as a treatment for newly diagnosed chronic lymphocytic leukemia, and lymphoma.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE